Conference Day Two - Thursday November 6, 2025

8:00 am Check-In & Light Breakfast

8:55 am Chair’s Opening Remarks

Refining Inflammasome-Driven Immune Modulation to Enable Meaningful Clinical Outcomes

9:00 am Spotlighting Phase II Clinical Data: Advancing GPCR19 Agonists for Patients with Atopic Dermatitis

Synopsis

  • Defining GPCR19’s role in inflammasome regulation through foundational immunology insights
  • Highlighting Phase II studies supporting GPCR19-targeting strategies for modulating immune pathways in atopic dermatitis
  • Uncovering the therapeutic potential of GPCR19 agonists across inflammatory skin conditions including diabetic ulcers, acne, etc.

9:30 am Immune Surveillance Upstream of NLRP3 Pathway: Clinical Insights on Diabetes & Retinal Disease

  • Brian Levy Chief Executive Officer, InflammX Therapeutics

Synopsis

  • Showcasing Xiflam (oral drug) targeting a cytoplasmic loop to close pathologically open Cx43 channels and shut down a priming signal for NLRP3 assembly
  • Unravelling the mechanisms of inhibiting a perpetuated inflammatory response without compromising patients’ immunity
  • Revealing updates on the ongoing Phase II clinical trial for intermediate AMD with QD dosed Xiflam (biomarkers, endpoints, and FDA discussions resulting in acceptance of study protocol)

Unravelling Pathway Biology to Spotlight Untouched Activation Routes & Other Disease Links

10:00 am First-in-Class Caspase-4/5 Inhibition: Unlocking New Frontiers in Inflammasome Therapeutics

Synopsis

  • Identifying highly selective small-molecule inhibitors of caspase-4/5 via a novel allosteric mechanism
  • Showcasing enhanced cellular potency, suppression of pyroptosis, and IL-18 release across multiple cell types
  • Evaluating clinical pathways and disease indications including IBD and hidradenitis suppurativa for redefined treatment strategies

10:30 am Morning Refreshments & Networking

11:15 am Tissue-Specific Regulation of Neutrophils: Citrullination, Polarization & NLRP3 Targeting

  • DENISA WAGNER PROFESSOR, SENIOR INVESTIGATOR, Harvard Medical School

Synopsis

  • Defining the role of NLRP3 activation in neutrophil polarization and its modulation through inhibition
  • Characterizing PAD4-mediated citrullination as a tissue-specific regulator of inflammasome formation and NETosis in neutrophils
  • Exploring ASC protein dispersion during NETosis as a driver of inflammasome amplification and a target for therapeutic intervention

11:45 am Roundtable Discussion: Inflammasomes at the Frontier: Charting the Next Move of Therapeutic Innovation

  • Hal Hoffman Professor, Pediatrics, University of California, San Diego

Synopsis

  • Comprehending the complexity of inflammasome signaling and how distinguishing pathways can inform more selective therapeutic approaches
  • Embracing novel molecular targets within and around inflammasome complexes and their potential to reshape anti-inflammatory drug development
  • Setting the scene for combination therapies though the role of inflammasomes in synergistic regimens across various disease indications

12:30 pm Exploring the Gut-Brain Axis: Inflammasome-Mediated Inflammation & Pharmacological Inhibition Strategies

  • Roberto De Luca Instructor in Neurology, Beth Israel Deaconess Medical Center (Harvard Medical School)
  • Roberto Negro Senior Scientist, IRCCS

Synopsis

  • Investigating the role of inflammasomes in gut inflammation and their impact on cancer development
  • Examining how gut-derived signals influence the nervous system, contributing to brain-gut axis communication
  • Dissecting pharmacological approaches targeting inflammasome activation to restore homeostasis within the gut-brain axis

1:00 pm Lunch & Networking

Introducing Delivery & Therapeutic Targeting Tactics for Inflammasome-Focused Drug Innovation

2:00 pm Novel Virus-Like-Particle (VLP)-Based Vaccines Targeting Inflammasomes & Tau Pathology in Alzheimer’s Disease

Synopsis

  • Exploring the mechanisms of inflammasome activation through NLRP3 signaling in Alzheimer’s pathogenesis
  • Enabling synergistic immunomodulation of tau aggregation and neuroinflammation to suggest a dual pathology model
  • Achieving active immunotherapy for Alzheimer’s disease through long-lasting, self-sustaining immune responses

2:30 pm Disrupting RHAMM-Target Interactions Within the NLRP3 Pathway Through Novel Peptide Inhibitors

Synopsis

  • Identifying a novel downstream target of RHAMM within the NLRP3 pathway that modulates inflammatory signaling
  • Revealing direct evidence of RHAMM’s interaction with the new target to elucidate the mechanism of this molecular engagement
  • Demonstrating how peptide-based and small molecule inhibitors effectively block this interaction to support precise immune modulation

2:45 pm Chair’s Closing Remarks

3:15 pm End of Conference Day Two

Full Event Guide
Pre-Conference Workshop Day
Day One